This site is intended for healthcare professionals only
Share this article

Dapagliflozin approved in the EU for treatment of CKD in people with and without type 2 diabetes

The sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin has been approved in the EU for the treatment of chronic kidney disease (CKD) both in people with type 2 diabetes and those without the condition.

The approval is based on positive results from the phase 3 DAPA-CKD trial, in which dapagliflozin significantly reduced the primary composite renal and cardiovascular outcome by 39% compared with placebo, and the secondary renal endpoint (sustained ≥50% decline in eGFR, end-stage renal disease or renal death) by 44%.

Commenting on the approval, Professor Hiddo Heerspink (University Medical Center Groningen, the Netherlands), the co-chair of the DAPA-CKD trial, said: “Today’s approval establishes dapagliflozin as the first SGLT2 inhibitor approved for the treatment of CKD regardless of diabetes status in the EU. Based on the unprecedented results from the DAPA-CKD Phase III trial, dapagliflozin delays disease progression, providing physicians a critical opportunity to improve the prognosis of patients with CKD.”

Dapagliflozin does not require dose adjustment based on kidney function; however, it should not be started in people with an eGFR <15 mL/min/m2. When used in people with type 2 diabetes, its glycaemic-lowering effects are reduced when eGFR is <45 mL/min/1.73 m2, and is likely absent in people with severe renal impairment. Therefore, if eGFR falls below 45 mL/min/1.73 m2, additional glucose-lowering treatment should be considered.

Related content
Prevention of diabetic maculopathy: Trial of oral medication begins
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.